Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study.

ABSTRACT: Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental doses as adjunctive therapy for patients critically ill with COVID-19. This was a two-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 diagnosis between March 1st and December 31st, 2020, were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the clinical outcomes of low-dose ascorbic acid as adjunctive therapy in COVID-19 afte

SUBMITTER: Al Sulaiman K 

PROVIDER: S-EPMC8417267 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature